Masimo announced its financial results for the fourth quarter and full-year ended December 28, 2024, on February 25, 2025. Fourth quarter 2024 consolidated revenue reached $600.7 million, representing a 9% increase over the prior year.
For the full year 2024, consolidated revenue was $2.09 billion, up 2.3% from fiscal year 2023, with non-GAAP diluted earnings per share at $4.40. The healthcare business demonstrated strong growth and earnings power, achieving a record year in customer contracts.
The company provided updated full-year 2025 guidance, projecting healthcare revenue of $1,500 million to $1,530 million, an 8-11% constant currency growth. Non-GAAP operating profit is expected to be $413 million to $428 million, with non-GAAP EPS in the range of $5.10 to $5.40, reflecting anticipated increased earnings and cash flow from strategic realignment efforts.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.